Merck Animal Health announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products issued a positive opinion for BRAVECTO 150 mg/ml powder and solvent for suspension for injection for dogs. The CVMP recommends the product for approval for the treatment and persistent killing of fleas and ticks for 12 months. If the European Commission adopts the recommendation, this injectable formulation of BRAVECTO can be used by or under the supervision of a veterinarian and for administration to dogs and puppies six months of age and older. Based on the CVMP’s recommendation, the EC is expected to issue a decision for marketing authorization in the European Union during the first quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Merck, Eisai provide update on Phase 3 LEAP-001 trial
- Merck discontinues trial evaluating Keytruda combination in NSCLC
- Merck reports Phase 2 results of coformulation for lung cancer
- White House to back controversial patent ploy to fight drug costs, STAT says
- Curis signs agreement for emavusertib/pembrolizumab combination melanoma study